Logo do repositório
 
Publicação

The importance of getting the dose right in the treatment of tuberculosis

2025-03-18Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorDudnyk, Andrii
dc.contributor.authorLutchmun, Wandini
dc.contributor.authorDuarte, Raquel
dc.contributor.authorLange, Christoph
dc.contributor.authorSvensson, Elin M.
dc.contributor.authoron behalf of the UNITE4TB Consortium
dc.date.accessioned2026-02-12T11:37:49Z
dc.date.available2026-02-12T11:37:49Z
dc.date.issued2025-03-18
dc.description.abstractPrescribing the optimal combination of anti-tuberculosis drugs at the right dose is a fundamental step to achieve successful treatment outcomes. To aid the decision, clinicians should consider multiple factors, such as body weight, age, results of drug susceptibility testing, risk of intolerance and potential drug-drug interactions. In this viewpoint, we outline different aspects of dose selection in the treatment of tuberculosis (TB) such as traditional pharmacokinetics/pharmacodynamics, population pharmacokinetics models, the importance of real-world evidence and clinical trial design in the development of shorter treatment regimens and the new TB drug pipeline. Therapeutic drug monitoring for rifampicin, linezolid and amikacin may significantly improve their risk-benefit profile promoting their responsible administration. Precision dosing of novel, repurposed or conventional TB drugs should ensure optimal efficacy, while minimising toxicity and the development of resistance.eng
dc.description.abstractShareable abstract: Getting the dose right in the treatment of tuberculosis (TB) is a key tool for safe and effective administration of existing anti-TB drugs and for acceleration of the development of new agents or regimens https://bit.ly/3V4ATyjeng
dc.description.sponsorshipThis project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 101007873. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e.V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research. C. Lange is supported by DZIF under grant agreement TTU-TB 02.709. A. Dudnyk received funding through the MSCA4Ukraine-project ID:1233336.
dc.identifier.citationBreathe (Sheff). 2025 Mar 18;21(1):240177. doi: 10.1183/20734735.0177-2024. eCollection 2025 Jan
dc.identifier.doi10.1183/20734735.0177-2024
dc.identifier.eissn2073-4735
dc.identifier.issn1810-6838
dc.identifier.pmid40104255
dc.identifier.urihttp://hdl.handle.net/10400.18/10912
dc.language.isoeng
dc.peerreviewedyes
dc.publisherEuropean Respiratory Society
dc.relationACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS
dc.relation.hasversionhttps://publications.ersnet.org/content/breathe/21/1/240177
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectTuberculosis
dc.subjectDose
dc.subjectAnti-Tuberculosis Drugs
dc.subjectPK/PD Modelling
dc.subjectCuidados de Saúde
dc.titleThe importance of getting the dose right in the treatment of tuberculosiseng
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS
oaire.awardURIhttp://hdl.handle.net/10400.18/10911
oaire.citation.issue1
oaire.citation.startPage240177
oaire.citation.titleBreathe
oaire.citation.volume21
oaire.fundingStreamResearch and Innovation action
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
relation.isProjectOfPublication9a7dbea5-95a2-4c5f-86ba-fd1737342fde
relation.isProjectOfPublication.latestForDiscovery9a7dbea5-95a2-4c5f-86ba-fd1737342fde

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Theimportancedoseright_treatmenttuberculosis_Dudnyk_2025.pdf
Tamanho:
334.6 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

CD - Artigos em revistas internacionais
INSA - Artigos em revistas internacionais